|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | The biological stress of early weaned piglets显示文摘Pigs experience biological stress such as physiological, environmental, and social challenges when weaned from the sow. The process of weaning is one of the most stressful events in the pig's life that can contribute to intestinal and immune system dysfunctions that result in reduced pig health, growth, and feed intake, particularly during the first week after weaning. Technological improvements in housing, nutrition, health, and management have been used to minimize some of the adverse effects of weaning stress, but a greater understanding of the biological impact of stress is needed to improve strategies to overcome weaning stress. The focus of this review paper is to briefly describe how the biological stress associated with weaning impacts intestinal morphology, structure, physiology, and intestinal immune responses that can impact subsequent production efficiencies such as growth, intake, morbidity, and mortality. | Joy M Campbell Joe D Crenshaw Javier Polo | 2013 | Journal of Animal Science and Biotechnology2013，4，2： | 83 |
| 2 | 帕博利珠单抗单用或与放疗联用治疗转移性非小细胞肺癌:两个随机试验的汇总分析显示文摘背景放疗可以提高整个机体对免疫治疗的应答。在Ⅱ期PEMBRO-RT研究和Ⅰ/Ⅱ期MDACC研究中,患有转移性非小细胞肺癌(NSCLC)的患者被随机分配入组,接受免疫治疗(帕博利珠单抗)+放疗联合疗法,或免疫治疗单一疗法。当上述2个研究单独分析时,联合疗法组显示出潜在获益。由于每个研究的样本量较小,缓解率和结局并未显示出统计学意义,然而却有显著的临床获益。因此,本研究进行汇总分析,来判断放疗是否会改善转移性NSCLC患者的免疫治疗应答。方法PEMBRO-RT和MDACC研究纳入标准:患者年龄≥18岁,患有转移性NSCLC,且有≥1处未经放疗照射的病灶,以便进行射野外应答监测。PEMBRO-RT研究纳入曾接受过化疗患者,MDACC研究纳入曾接受过治疗或新诊断患者。2个研究中的患者均未接受过免疫治疗。在PEMBRO-RT研究中患者被等比例随机分配入组,并根据吸烟状态进行分层(分为<10年组和≥10年组)。MDACC研究的患者根据放疗计划可行性被等比例随机分配入2个受试组。由于联合治疗组的干预本质,每个研究中的放疗均不适用盲法。在2个研究中,不论是否进行放疗,均静脉滴入帕博利珠单抗(每3周200 mg)。在PEMBRO-RT研究中,在放疗(24 Gy 3次分割照射)结束后1周给予第1剂帕博利珠单抗。在MDACC研究中,在第1次放疗(50 Gy 4次分割照射或45 Gy 15次分割照射)同时给予帕博利珠单抗。仅检测未经照射病灶的应答。本研究的终点为最佳射野外(远隔)应答率(ARR)、最佳射野外疾病控制率(ACR)、12周时ARR、12周时ACR、无进展生存期(PFS)和总生存期(OS)。2个研究的意向治疗(ITT)人群均纳入分析。PEMBRO-RT研究(NCT02492568)和MDACC研究(NCT02444741)均在ClinicalTrials.gov上注册。发现纳入148例患者,76例接受帕博利珠单抗治疗,72例接受帕博利珠单抗+放疗治疗。所有患者随访时间中位数为33个月[四分位距(IQR):32.4~33.6]。148例患者中124例(84%)组织学特征为非鳞癌,111例(75%)患者曾经接受过化疗。组间没有基线特征差异,包括PD-L1表达状态和转移灶体积。最常见的照射部位为肺转移灶(39%,28/72)、胸腔内淋巴结(21%,15/72)和非原发灶(17%,12/72)。帕博利珠单抗组和联合治疗组的最佳ARR分别为19.7%(15/76)和41.7%(30/72),OR=2.96,95%CI:1.42~6.20,P=0.0039;最佳ACR分别为43.4%(33/76)和65.3%(47/72),OR=2.51,95%CI:1.28~4.91,P=0.0071;PFS中位数分别为4.4(IQR:2.9~5.9)和9.0个月(IQR:6.8~11.2),HR=0.67,95%CI:0.45~0.99,P=0.045;OS中位数分别为8.7(IQR:6.4~11.0)和19.2个月(IQR:14.6~23.8),OR=0.67,95%CI:0.54~0.84,P=0.0004。在汇总分析中没有发现新的安全问题。解读帕博利珠单抗免疫疗法+放疗显著提高转移性NSCLC患者的应答和改善治疗结局。这些结果需要在三期临床试验中进行验证。 | 陈大卫(翻译) 于金明(校对) Willemijn S M E Theelen Vivek Verma Brian P Hobbs Heike M U Peulen Joachim G J V Aerts Idris Bahce Anna Larissa N Niemeijer Joe Y Chang Patricia M de Groot Quynh-Nhu Nguyen Nathan I Comeaux George R Simon Ferdinandos Skoulidis Steven H Lin Kewen He Roshal Patel John Heymach Paul Baas James W Welsh | 2021 | 中华肿瘤防治杂志2021，28，24： | 49 |
| 3 | Alcohol,inflammation,and gut-liver-brain interactions in tissue damage and disease development显示文摘Chronic inflammation is often associated with alcoholrelated medical conditions. The key inducer of such inflammation, and also the best understood, is gut microflora-derived lipopolysaccharide (LPS). Alcohol can significantly increase the translocation of LPS from the gut. In healthy individuals, the adverse effects of LPS are kept in check by the actions and interactions of multiple organs. The liver plays a central role in detoxifying LPS and producing a balanced cytokine milieu. The central nervous system contributes to anti-inflammatory regulation through neuroimmunoendocrine actions. Chronic alcohol use impairs not only gut and liver functions, but also multi-organ interactions, leading to persistent systemic inflammation and ultimately, to organ damage. The study of these interactions may provide potential new targets for therapeutic intervention. | H Joe Wang Samir Zakhari M Katherine Jung | 2010 | World Journal of Gastroenterology2010，16，11： | 26 |
| 4 | 肾脏黏液样小管状和梭形细胞癌临床病理分析显示文摘目的探讨肾脏黏液样小管状和梭形细胞癌(mucinous tubular and spindle cell carcinoma, MTSCCa)的临床病理特征和鉴别诊断要点及生物学行为。方法对4例MTSCCa标本进行组织病理学和免疫组化染色观察,并复习临床资料及相关文献。结果该肿瘤好发于女性,发病年龄17~82岁(平均53岁),临床症状不明显。组织学:肿瘤与周围肾组织分界清楚,切面实性、灰白色,肿瘤细胞形态呈双相(小管状和梭形细胞)或三相(小管状、梭形和脊索瘤样或黏液样)。其他组织学表现:泡沫样巨噬细胞聚集、典型的透明细胞和乳头状或乳头结构。免疫组化显示复合性免疫表型。结论MTSCCa是一种罕见的低级别多形性肿瘤,组织学谱系在不断扩大,免疫组化表型及组织学形态与乳头状肾细胞癌(PRCCa)有重叠。 | 张仁亚 曾涛 刘飞飞 任玉波 M Joe Ma 马洪军 许俊龙 赵丽华 刘建丽 林凡忠 | 2007 | 临床与实验病理学杂志2007，23，3： | 9 |
| 5 | 早期断奶仔猪的生物学应激显示文摘当仔猪断奶后离开其母猪时,会遭遇到生物学应激,如生理的、环境的和社会的挑战。断奶过程是猪一生中最具应激性的事件,会造成肠道和免疫系统的机能障碍,结果导致猪健康状况、生长性能和采食量的降低,特别是断奶后首周内。饲养系统、营养、健康和管理技术的改进已被用来将断奶应激的一些不利影响降至最小程度,但是更好地了解应激的生物学作用,为改进能够克服断奶应激的策略所需要的。本综述的重点,是简要地描述与断奶有关的生物学应激是如何通过影响肠道形态、结构、生理和肠道免疫反应,进而可能会影响生产效率,如生长、采食量、发病率和死亡率。 | 陈建康 Joy M Campbell Joe D Crenshaw Javier Polo | 2014 | 国外畜牧学(猪与禽)2014，0，S1： | 8 |
| 6 | Protective role of PI3-kinase/Akt/eNOS signaling in mechanical stress through inhibition of p38 mitogenactivated protein kinase in mouse lung显示文摘 | Xin-qi PENG Mahendra DAMARLA Jarrett SKIRBALL Stephanie NONAS Xiao-ying WANG Eugenia J HAN Emile J HASAN Xuan CAO Adel BOUEIZ Rachel DAMICO Rubin M TUDER Alfred M SClUTO Dana R ANDERSON Joe GNGARCIA David A KASS Paul M HASSOUN Jun-tian ZHANG | 2010 | Acta Pharmacologica Sinica2010，31，2： | 6 |
| 7 | Analysis of a Successful Immune Response against Hepatitis C Virus显示文摘 | Stewart Cooper Ann L Erickson Erin J Adams Joe Kansopon Amy J Weiner David Y Chien Michael Houghton Peter Parham Christopher M Walker | 1999 | Immunity1999，，4： | 3 |
| 8 | 肾脏黏液性小管状和梭形细胞癌研究进展显示文摘肾脏黏液性小管状和梭形细胞癌(mucinous tubular and spindlecell carcinoma,MTSCCa)是新确定一种罕见的低度恶性肾上皮性肿瘤。多见于青年女性,临床上无明显症状。以往常被诊断为梭形细胞(肉瘤样)肾细胞癌或不能分类的肾细胞癌。大体肿物界限清楚,切面实性、灰白色。组织学特点是肿瘤细胞排列成管状和实性梁索状漂浮于黏液性基质中,Alcianblue染色阳性。免疫组化显示复合性免疫表型。临床预后好,可复发并具有潜在远处转移的可能,应重视与其他肾脏良恶性肿瘤(后肾腺瘤、肉瘤样癌和集合管癌等)相鉴别。 | 张仁亚 任玉波 M Joe Ma | 2007 | 中华肿瘤防治杂志2007，14，21： | 3 |
| 9 | Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab显示文摘AIM:To investigate the safety and efficacy of adding bevacizumab to first-line chemotherapy in metastatic colorectal cancer patients with peritoneal disease.METHODS:We compared rates of gastrointestinal perforation in patients with metastatic colorectal cancer and peritoneal disease receiving first-line chemotherapy with and without bevacizumab in three distinct cohorts:(1) the AGITG MAX trial(Phase Ⅲ randomised clinical trial comparing capecitabine vs capecitabine and bevacizumab vs capecitabine,bevacizumab and mitomycin C);(2) the prospective Treatment of Recurrent and Advanced Colorectal Cancer(TRACC) registry(any first-line regimen ± bevacizumab);and(3) two cancer centres in New South Wales,Australia [Macarthur Cancer Therapy Centre and Liverpool Cancer Therapy Centre(NSWCC) from January 2005 to Decenber 2012,(any first-line regimen ± bevacizumab).For the AGITG MAX trial capecitabine was compared to the other two arms(capecitabine/bevacizumab and capecitabine/bevacizumab/mitomycin C).In the AGITG MAX trial and the TRACC registry rates of gastrointestinal perforation were also collected in patients who did not have peritoneal metastases.Secondary endpoints included progression-free survival,chemotherapy duration,and overall survival.Time-toevent outcomes were estimated using the Kaplan-Meier method and compared using the log-rank test.RESULTS:Eighty-four MAX,179 TRACC and 69 NSWCC patients had peritoneal disease.There were no gastrointestinal perforations recorded in either the MAX subgroup or the NSWCC cohorts.Of the patients without peritoneal disease in the MAX trial,4/300(1.3%) in the bevacizumab arms had gastrointestinal perforations compared to 1/123(0.8%) in the capecitabine alone arm.In the TRACC registry 3/126(2.4%) patients who had received bevacizumab had a gastrointestinal perforation compared to 1/53(1.9%) in the chemotherapy alone arm.In a further analysis of patients without peritoneal metastases in the TRACC registry,the rate of gastrointestinal perforations was 9/369(2.4%) in the chemotherapy/bevacizumab group and 5/177(2.8%) in the chemotherapy alone group.The addition of bevacizumab to chemotherapy was associated with improved progression-free survival in all three cohorts:MAX 6.9 m vs 4.9 m,HR = 0.64(95%CI:0.42-1.02);P = 0.063;TRACC 9.1 m vs 5.5 m,HR = 0.61(95%CI:0.37-0.86);P = 0.009;NSWCC 8.7 m vs 6.8 m,HR = 0.75(95%CI:0.43-1.32);P = 0.32.Chemotherapy duration was similar across the groups.CONCLUSION:Patients with peritoneal disease do not appear to have an increased risk of gastrointestinal perforations when receiving first-line therapy with bevacizumab compared to systemic therapy alone. | Aflah Roohullah Hui-Li Wong Katrin M Sjoquist Peter Gibbs Kathryn Field Ben Tran Jeremy Shapiro Joe Mckendrick Desmond Yip Louise Nott Val Gebski Weng Ng Wei Chua Timothy Price Niall Tebbutt Lorraine Chantrill | 2015 | World Journal of Gastroenterology2015，21，17： | 3 |
| 10 | 用PDE-5抑制剂治疗勃起功能障碍的男性患者中前列腺癌的发生率:回顾性研究显示文摘本研究比较了用PDE-5抑制剂治疗勃起功能障碍(ED)7年的男性患者和与这些患者年龄及各种风险因素相似的7年内不使用PDE一5抑制剂治疗ED的男性患者中前列腺癌发生率的情况。通过分析2000年到2006年的电子病例和数据库,以年龄在50至69岁,2000年前无前列腺癌病史的ED患者作为研究对象。这些患者被分为两组:2362名曾用PDE-5抑制剂治疗的男性和2612名不曾使用过该药物的男性。比较每组的人口数据。在研究期内:97名(4.1%)接受过PDE-5抑制剂治疗的ED患者被诊断出患了前列腺癌,在非PDE-5抑制剂治疗组中,258名(9.9%)被诊断出患了前列腺癌(P〈O.0001)。在非洲裔美国人中,接受PDE-5抑制剂治疗的比例比不用的比例高(10.5%VS.7.1%,P〈0.0001)。接受过PDE-5治疗的患者,其前列腺特异性抗原增高的比例比较低(10.0%vs.13.1%,P=0.0008),但良性前列腺增生的比例比较高(38.4%vs.35.1%,P=0.0149)。接受PDE-5抑制剂治疗ED的男性不易患前列腺癌(调整后的优势比为0.4,95%CI:0.3—0.5,P〈0.0001)。我们的研究数据表明:用PDE-5抑制剂治疗ED的男性倾向于不易患前列腺癌。还需要进行更多的研究。 | Anthony H Chavez K Scott Coffield M Hasan Rajab Chanhee Joe | 2013 | Asian Journal of Andrology2013，15，2： | 2 |
| 11 | Airborne hyperspectral imagery and linear spectral unmixing for mapping variation in corp yield显示文摘 | Cheng hai Yang James H Everitt Joe M Bradford | 2007 | Precision Agric2007，8，： | 1 |
| 12 | Sustained use of a household—scale water filtration device in rural Cambodia显示文摘 | Brown Joe Proum S Sobsey M D | | 0，，03： | 1 |
| 13 | A functional Link between heine oxygenase-1 and tristetraprolin in the anti- inflammatory effects of nicotine显示文摘 | JAMAL UDDIN M JOE Y ZHENG M | 2013 | Free Radical Biology Medicine2013，65，： | 1 |
| 14 | Simultaneous determination of six penicillins in cow's raw milk by a multiresidue high-performance liquid chromatographic method 显示文摘 | Sorensen L K Rasmussen B M Boison Joe O | 1997 | Journal of Chromatography B: Biomedical Sciences and Applications1997，694，2： | 1 |
| 15 | Preparation and application of organo- minerals as sorbents of phenol, benzene and toluene显示文摘 | SANG M K JOE B D | 2001 | Ap- plied Clay Science2001，，18： | 1 |
| 16 | Effect of surfactants on codeposition of PTFE particles with electroless Ni-P coating 显示文摘 | Get M D Joe H B | 2002 | Matcr Chem Phys2002，76，1： | 1 |
| 17 | The dimensionality of the maslach burnout inventory across small business owners and educators 显示文摘 | JAMES S B DWANE H D JOE M R | 2000 | Journal of Vocational Behavior2000，56，： | 1 |
| 18 | Multivariate process monitoring and fault diagnosis by multi-scale PCA显示文摘 | Manish M Henry Joe Q S | 2002 | Computers and Chemical Engineering2002，26，9： | 1 |
| 19 | Oxygen-derived free radicals in postischemic tissue injury 显示文摘 | Joe M McCord Ph D | 1985 | New Engl J Med1985，312，3： | 1 |
| 20 | Extraction and characteriza- tion of pepsin-solubihsed collage from fins, scales, skins, bones and swim bladders of bighead carp (Hypophthal- michthys nobilis) 显示文摘 | LIU D S LI L JOE M | 2012 | Food Chemistry2012，133，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员